
Tirosint-SOL is owned by IBSA (Institut Biochimique SA), a privately held Swiss pharmaceutical company headquartered in Lugano, and distributed in the United States by its subsidiary IBSA Pharma Inc. of Parsippany, New Jersey. The FDA approved Tirosint-SOL in December 2016 as the first liquid levothyroxine formulation, and it launched in the US market in February 2019.
Parent Company
Founded
2016
Status
Private
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Tirosint-SOL | IBSA Institut Biochimique S.A. | Product line |
IBSA built its thyroid franchise on a single insight: many levothyroxine patients absorb the drug poorly because of excipients, food interactions, or gastrointestinal conditions, and a purer formulation could perform more consistently. The Tirosint softgel capsule, containing levothyroxine in gelatin with glycerin and water, had applied that idea since the mid-2000s.
Tirosint-SOL extended it to a liquid. The oral solution contains only levothyroxine, glycerol, and water in a single-dose ampule, eliminating every excipient that can interfere with absorption: no dyes, gluten, lactose, alcohol, sugar, or preservatives. It can be swallowed directly or diluted in water, which also makes it usable for children, elderly patients, and anyone who cannot take tablets.
IBSA filed the New Drug Application in February 2016, and the FDA approved Tirosint-SOL on December 15, 2016, under NDA 206977. It was, and remains, the only FDA-approved liquid levothyroxine formulation. The product had already been studied and marketed in Europe, where liquid levothyroxine had a longer clinical history.
The US launch came later. IBSA Pharma announced on February 27, 2019, that Tirosint-SOL was available through its Tirosint Direct program, with pharmacy availability starting March 1, 2019. The delay between approval and launch reflected the commercial ramp-up for a niche product in a market dominated by tablets.
In January 2021, the FDA approved additional strengths expanding the range to 12 dosage options, and in December 2023 it granted two further label changes. The product continues to be detailed to endocrinologists and thyroid specialists as the liquid alternative within IBSA's levothyroxine family.
What does IBSA own?
IBSA owns and markets pharmaceutical products across 10 therapeutic areas under three primary brand names: IBSA (corporate brand covering all therapeutic areas), Monurella (urology and urinary tract health), and Lutinus (reproductive medicine and fertility). The company's portfolio includes both prescription pharmaceuticals and consumer health products sold through pharmacies and healthcare providers.
Is IBSA publicly traded?
No, IBSA Institut Biochimique S.A. is a privately held family-owned company. It is not listed on any stock exchange and does not have public shareholders. The company has maintained its private ownership structure since its founding in 1945, which allows it to pursue long-term strategies without the pressure of public market expectations.
Who founded IBSA?
IBSA was founded in 1945 by Dott. Angelo Cavalli in Lugano, Switzerland. Cavalli established the company as a biochemical research institute. The company remained relatively small until the 1990s, when CEO and President Arturo Licenziati began a period of sustained international expansion that has continued for over 40 years.
Where is IBSA headquartered?
IBSA is headquartered in Lugano, in the canton of Ticino, Switzerland. The company's largest manufacturing facility, the cosmos plant, is also located at the Lugano headquarters. IBSA maintains additional manufacturing operations in Italy and China, along with 20 subsidiaries across Europe, China, and the United States.
How many brands does IBSA own?
IBSA owns three primary brands: IBSA (the corporate brand for pharmaceutical products across all therapeutic areas), Monurella (for urology and urinary tract health products), and Lutinus (for reproductive medicine and fertility products). The company's product portfolio spans 10 therapeutic areas, with many products marketed under the IBSA corporate brand.
Who owns IBSA?
IBSA is privately owned by the founding family. The company is controlled through private holding structures, with no external investors or parent organization. CEO and President Arturo Licenziati has led the company for 40 years, maintaining the family's ownership and strategic control. The company has never sought public listing or external investment.
What is IBSA's revenue?
IBSA reported turnover of approximately CHF 1.089 billion in its most recent disclosed figures. The company reached CHF 986 million in 2023, representing 10 percent growth over the prior year. Europe is the company's largest market, followed by the Americas, which grew at 18.3 percent in 2023. IBSA employs over 2,500 people across its global operations.
The product has a clean post-launch record, with no major recalls reported since its 2019 US availability. Its regulatory activity has been routine label and strength supplements.
Category-level issues apply: levothyroxine is a narrow therapeutic index drug, so clinicians watch for potency consistency, and some patients and practitioners remain unfamiliar with liquid dosing equivalences versus tablets. Price is the recurring criticism: the product is among the most expensive levothyroxine options, and access depends heavily on insurance coverage or IBSA's direct program.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Ibsa | Switzerland | 2006 | Premium | United states | All Genders | |
| Pfizer | USA | 2001 | Mass market | United states | All Genders | |
| Abbvie | USA | 1955 | Mass market | United states | All Genders | |
| Amneal Pharmaceuticals | USA | 2000 | Mass market | United states | All Genders | |
| Abbvie | USA | 1900 | Mass market | United states | All Genders |
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Healthcare PharmaceuticalsOwned by Pfizer Inc.
Pfizer's levothyroxine brand for hypothyroidism, FDA approved in 2001 and inherited through the 2011 King Pharmaceuticals acquisition.
Healthcare PharmaceuticalsOwned by AbbVie Inc.
AbbVie's levothyroxine brand for hypothyroidism, first marketed in 1955 and long among the most prescribed medications in the United States.
Healthcare PharmaceuticalsOwned by Amneal Pharmaceuticals, Inc.
Levothyroxine tablet for hypothyroidism, the first FDA-approved levothyroxine product, manufactured by Jerome Stevens Pharmaceuticals and distributed by Amneal.
Healthcare PharmaceuticalsOwned by AbbVie Inc.
AbbVie's natural desiccated thyroid brand derived from porcine thyroid glands, used for hypothyroidism for more than a century and acquired through Forest, Actavis, and Allergan.
Market Positioning: Tirosint-SOL competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by IBSA Institut Biochimique S.A., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Pfizer Inc.
Pfizer's levothyroxine brand for hypothyroidism, FDA approved in 2001 and inherited through the 2011 King Pharmaceuticals acquisition.
Levoxyl is owned by Pfizer Inc., a public company, a different structure than Tirosint-SOL's parent.
Healthcare PharmaceuticalsOwned by AbbVie Inc.
AbbVie's levothyroxine brand for hypothyroidism, first marketed in 1955 and long among the most prescribed medications in the United States.
Synthroid is owned by AbbVie Inc., a public company, a different structure than Tirosint-SOL's parent.
Healthcare PharmaceuticalsOwned by Amneal Pharmaceuticals, Inc.
Levothyroxine tablet for hypothyroidism, the first FDA-approved levothyroxine product, manufactured by Jerome Stevens Pharmaceuticals and distributed by Amneal.
Unithroid is owned by Amneal Pharmaceuticals, Inc., a public company, a different structure than Tirosint-SOL's parent.
Healthcare PharmaceuticalsOwned by ADARx Pharmaceuticals, Inc.
Biotechnology brand of ADARx Pharmaceuticals, the San Diego siRNA company that listed on Nasdaq in September 2026.
ADARx operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
Alcon operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.